PT  - JOURNAL ARTICLE
AU  - Jean W. Liew
AU  - S. Reza Jafarzadeh
AU  - Maureen Dubreuil
AU  - Susan R. Heckbert
AU  - Stephen J. Mooney
AU  - Matthew A. Brown
AU  - Mariko L. Ishimori
AU  - John D. Reveille
AU  - Michael M. Ward
AU  - Michael H. Weisman
AU  - Lianne S. Gensler
TI  - The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort
AID  - 10.3899/jrheum.210332
DP  - 2022 Mar 01
TA  - The Journal of Rheumatology
PG  - 274--280
VI  - 49
IP  - 3
4099  - http://www.jrheum.org/content/49/3/274.short
4100  - http://www.jrheum.org/content/49/3/274.full
SO  - J Rheumatol2022 Mar 01; 49
AB  - Objective Individuals with ankylosing spondylitis (AS) have a greater cardiovascular (CV) risk than those in the general population. The effect of tumor necrosis factor inhibitors (TNFis) on CV risk, including on the development of hypertension (HTN), remains unclear, with some data suggesting higher risk. We assessed the association of TNFi use with incident HTN in a longitudinal AS cohort.Methods Adults with AS enrolled in a prospective cohort in 2002–2018 were examined every 4–6 months. TNFi use during the preceding 6 months was ascertained at each study visit. We defined HTN by patient-reported HTN, antihypertensive medication use, or, on 2 consecutive visits, systolic blood pressure (BP) ≥ 140 mmHg or diastolic BP ≥ 90 mmHg. We evaluated the association between TNFi use and the development of HTN with marginal structural models, estimated by inverse probability-of-treatment weighting, to account for time-dependent confounders and informative censoring. Potential confounders included age, sex, race, site, nonsteroidal antiinflammatory drug use, and disease activity.Results We included 630 patients without baseline HTN and with at least 1 year of follow-up. Of these, 72% were male, mean age was 39 ± 13 years, and 43% used TNFi at baseline. On follow-up (median 5 yrs), 129 developed incident HTN and 163 started on TNFi during follow-up. TNFi use was not associated with incident HTN (adjusted HR 1.10, 95% CI 0.83–1.37).Conclusion In our prospective AS cohort, TNFi use was not significantly associated with incident HTN.